Bristol Reyataz (atazanavir) review
Executive Summary
Bristol-Myers Squibb's protease inhibitor Reyataz (atazanavir) for HIV treatment with other antiretrovirals will be reviewed by FDA's Antiviral Drugs Advisory Committee at its May 13 meeting. Bristol filed NDAs for capsule and powder formulations of atazanavir on Dec. 20...